ArriVent BioPharma, Inc. Common Stock Cash Flow Conversion Efficiency
ArriVent BioPharma, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, ArriVent BioPharma, Inc. Common Stock (AVBP) has a cash flow conversion efficiency ratio of -0.108x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-39.58 Million) by net assets ($366.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ArriVent BioPharma, Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. This chart illustrates how ArriVent BioPharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AVBP live share price for real-time trading data and today's change.
ArriVent BioPharma, Inc. Common Stock Cash Flow Conversion Ratio Explained
ArriVent BioPharma, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ArriVent BioPharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ArriVent BioPharma, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see ArriVent BioPharma, Inc. Common Stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
-0.096x |
|
Inspur Software Co Ltd
SHG:600756
|
-0.037x |
|
Basellandschaftliche Kantonalbank
SW:BLKB
|
-0.313x |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
0.028x |
|
Whirlpool S.A
SA:WHRL3
|
0.421x |
|
Sweetgreen Inc
NYSE:SG
|
-0.037x |
|
Campus Activewear Limited
NSE:CAMPUS
|
-0.029x |
|
Indian Metals & Ferro Alloys Limited
NSE:IMFA
|
0.121x |
Annual Cash Flow Conversion Efficiency for ArriVent BioPharma, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. Review how financially flexible is ArriVent BioPharma, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $307.22 Million | $-160.59 Million | -0.523x | -91.82% |
| 2024-09-30 | $257.65 Million | $-70.21 Million | -0.273x | +26.17% |
| 2023-09-30 | $151.30 Million | $-55.84 Million | -0.369x | -47.58% |
| 2022-09-30 | $174.46 Million | $-43.63 Million | -0.250x | +18.10% |
| 2021-09-30 | $41.22 Million | $-12.59 Million | -0.305x | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more